Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter could ease heart drug dependence in shock patients

NCT ID NCT05027529

Disease control Sponsor: Christian Schulze Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding a special blood filter called CytoSorb to standard ECMO support helps people with cardiogenic shock (a severe form of heart failure). The filter aims to remove inflammatory substances from the blood. Researchers measured how much heart-support medication patients needed after 72 hours. The trial included 42 critically ill adults and compared those getting ECMO plus the filter to those getting ECMO alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CytoSorb device (a filter that removes inflammatory substances from the blood)
What this could lead to
If it works, this could point toward a way to reduce the need for strong heart medications in patients on ECMO for cardiogenic shock.
What could go wrong
This is a small, early-stage trial with only 42 patients, so results may not apply broadly. The device adds complexity and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

May 2021

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cardiogenic shock of any cause and indication for VA-ECMO * Age between 18 and 80 * Signed informed consent Exclusion Criteria: * Current participation in another interventional trial * Pregnancy * Current immunosuppressive or immunomodulatory therapy * Contraindications to VA-ECMO implantation. * Patients with pre - existing sepsis (raised CPR, positive PCT, leukozytosis, fever, positive blood cultures). * Shock duration\> 12 h before evaluation. * Severe PVD (peripheral vessel disease) making ECMO-implantation impossible. * Aortic valve insufficiency / stenosis at least II °. * Age \> 80 years. * CNS disease with fixed, dilated pupils (not drug-induced). * Severe concomitant disease with limited life expectancy \<6 months. * CPR\> 60min. * Shock due to other reasons * HIT positive (Heparin induced thrombocytopenia) * Very low platelet counts (\< 20,000/µl) * Body weight less than 45 kg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiogenic shock multiple organ dysfunction syndrome Shock, Cardiogenic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock

Contacts and locations

Locations

  • Jena University Hospital, Department of Cardiology

    Jena, Thuringia, 07747, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.